Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Schizophrenia: Omega-3 supplementation does not improve symptoms and hostility

Key clinical point: Omega-3 fatty acid supplementation does not show any significant improvements in symptoms and hostility in patients with schizophrenia.

Major finding: At 4 and 8 weeks, fish oil and placebo groups had a significant reduction in the total positive, negative, and total scale of the Positive and Negative Syndrome Scale score and the scores of hostility; however, no significant differences were observed between both the groups.

Study details: Patients with schizophrenia treated with antipsychotics were randomly assigned to receive a supplement with either fish oil (n = 32) or placebo (n = 35).

Disclosures: This study was supported by grants from The Three-Year Action Plan for The Construction of Public Health System in Shanghai, the National Natural Science Foundation of China, and Quantitative evaluation based strategic research of interventions on relapse of schizophrenia. The authors declared no conflicts of interest.


Qiao Y et al. Front Psychiatry. 2020 Apr 21. doi: 10.3389/fpsyt.2020.00312.